• Lipocine Inc LPCN.OQ reported quarterly adjusted earnings of $1.86​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -42 cents. The lone analyst forecast for the quarter was for a loss of 40 cents per share.

• Revenue rose 1,514.8% to $3.49 million from a year ago; analysts expected $2.61 million.

• Lipocine Inc's reported EPS for the quarter was $1.86​.

• The company reported quarterly net income of $10.12 million.

• Lipocine Inc shares had fallen by 34.2% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 8.1% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Lipocine Inc is $10.00

This summary was machine generated from LSEG data March 13 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)